TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01338532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A 12 week supervised exercise program and patient education
Description: The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.~All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
Study: NCT02742805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D (4,000 IU/day)
Description: High Dose of 4,000 IU/day.
Study: NCT04303299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral
Description: Anti virus treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral
Description: Anti virus treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral
Description: Anti virus treatment
Study: NCT04186507

Intervention type: COMBINATION_PRODUCT
Intervention: Smartwatch with integrated Li+ sensor (provided by Spectrophon LTD)
Description: To confirm that Li+ is detectable in sweat using Macroduct Sweat Collection System for sweat collection.~Current studies demonstrate that Li+ can be detected in saliva and in sweat. To confirm it, patients that are on treatment with Li+ will be recruited for this aim; sweat will be collected and checked for Li+ levels.~To develop the algorithm for Spectrophon LTD biosensors for Li+ levels measurement in sweat that will allow assessing the level of Li+ in blood.~To evaluate the accuracy and the efficacy of biosensors developed by Spectrophon LTD for Li+ detection in sweat.~Following positive results in previous objectives, clinical trial will be conducted to estimate the suitability, efficacy and accuracy of developed biosensors for non-invasive detection of Li+ in sweat.
Study: NCT00945230

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Re-section of a large left anterior cranial fossa meningioma
Description: Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
Study: NCT03563365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replenix Power of 3 Cream with resveratrol
Description: Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replenix Power of 3 Cream with resveratrol
Description: Cosmetic product containing Green Tea Polyphenols, Resveratrol, Caffeine USP, Bisabolol Cucumber extract, Chamomile extract, Rosemary extract, Squalane, Soy Phospholipids

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene and Benzoyl peroxide gel, 0.1%/2.5%
Description: FDA approved topical agent for the treatment of acne
Study: NCT02661217

Intervention type: DRUG
Group type: OTHER
Intervention: LCZ696
Description: LCZ696 film-coated tables were supplied to the investigators. Tablets were taken with a glass of water, and were administered with or without food.~The target dose of LCZ696 was 200 mg twice daily. Starting dose of LCZ696 was either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient.
Study: NCT02742805

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (400 IU/day)
Description: Low Dose of 400 IU/day.
Study: NCT03563365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene and Benzoyl peroxide gel, 0.1%/2.5%
Description: FDA approved topical agent for the treatment of acne
Study: NCT04203420

Intervention type: OTHER
Intervention: screening and confirmatory tests
Description: screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test

Intervention type: OTHER
Intervention: screening and confirmatory tests
Description: screening test is a blood test of the ratio of plasma aldosterone concentration(PAC) and direct renin concentration(DRC), confirmatory test is Captopril Challenge test
Study: NCT01919216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Citalopram
Study: NCT02346513

Intervention type: DEVICE
Intervention: Ceramic on Metal Articulation
Description: Patients have THA with ceramic on metal articulation

Intervention type: DEVICE
Intervention: Non-Ceramic on Metal Articulation
Description: Patients have THA with non-ceramic on metal articulation
Study: NCT01716585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Capsule (double-blind treatment period), tablet (open-label treatment period)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-450/r/ABT-267
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABT-333
Description: Tablet
Study: NCT02134678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-system therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: cognitive therapy
Study: NCT02692378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate 500mg capsules
Description: Defined by active substance and brand names not specified in protocol
Study: NCT01636128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: difluoromethylornithine
Description: 500 mg oral for 14 days, combined with sulindac for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: difluoromethylornithine
Description: 500 mg oral for 14 days, combined with sulindac for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac
Description: 150 mg oral for 15 days, combined with DFMO for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulindac
Description: 150 mg oral for 15 days, combined with DFMO for 14 days
Study: NCT01620528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elagolix
Description: oral tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral tablet
Study: NCT00861328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na and irinotecan
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.~The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON 01910.Na and oxaliplatin
Description: ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.~The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent.
Study: NCT03549559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Martinostat
Description: Imaging probe for evaluating the activity of histone deacetylase in the heart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-Martinostat
Description: Imaging probe for evaluating the activity of histone deacetylase in the heart

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 11C-Martinostat
Description: Imaging probe for evaluating the activity of histone deacetylase in the heart
Study: NCT03549559

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET-MRI
Description: Siemens PET-MR Scanner (Biograph MMR)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET-MRI
Description: Siemens PET-MR Scanner (Biograph MMR)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PET-MRI
Description: Siemens PET-MR Scanner (Biograph MMR)
Study: NCT01254825

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Block, Ropivacain
Description: Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Adductor Canal Block, Placebo (saline)
Description: Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
Study: NCT02036008

Intervention type: OTHER
Group type: OTHER
Intervention: Liver MRI with Gdfos
Description: Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.~This study will be performed within 4 weeks of the MRI study with EcGd.
Study: NCT02742805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Standard of care dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Standard of care dose.
Study: NCT02748148

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication therapy management
Description: Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
Study: NCT01350167

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Screening
Description: Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.~Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.
Study: NCT02390778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Debriefing
Description: Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: leisure activity (film showing)
Study: NCT01716585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ribavirin
Description: Capsule
Study: NCT02582008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement
Description: Given NRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Given PO
Study: NCT01142011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).~The infusion will be administered over a minimum period of 1 hour.
Study: NCT04787146

Intervention type: OTHER
Intervention: No intervention
Description: Once the patient is included, a drug assessment is carried out as part of the treatment and then an compliance questionnaire is submitted to him.
Study: NCT06518330

Intervention type: DRUG
Intervention: Intake of Methylphenidate
Description: Intake of Methylphenidate
Study: NCT01142362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3400X
Description: DNA plasmids delivered via IM injection + electroporation using CELLECTRA device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3400X
Description: DNA plasmids delivered via IM injection + electroporation using CELLECTRA device

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3400X
Description: DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
Study: NCT02811367

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HPV test
Description: Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
Study: NCT02811640

Intervention type: OTHER
Intervention: Study Participants
Description: IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
Study: NCT03055806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 400 mg
Description: IX-01 400 mg caplet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo caplet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo caplet(s)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo caplet(s)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 800 mg
Description: IX-01 800 mg (Two 400 mg caplets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IX-01 1200 mg
Description: IX-01 1200 mg (Three 400 mg caplets)
Study: NCT00522652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-478
Description: Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
Study: NCT02690506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Study: NCT04464876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SATURN TA System
Description: SATURN TA TMVR Device implanted
Study: NCT03464929

Intervention type: DEVICE
Intervention: Airtraq indirect laryngoscopy
Description: Attempt to intubation using the Airtraq device

Intervention type: DEVICE
Intervention: King Vision indirect laryngoscopy
Description: Attempt to intubation using the King Vision device
Study: NCT03474991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestamine®
Description: Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celestamine®
Description: Children in KIDS-STEP will be receiving either oral betamethasone (Celestamine®) or oral placebo dosed once daily for two consecutive days. Celestamine® N 0.5 liquidum is a betamethasone solution and will be used in the active comparator arm. Study medication will be administered orally once a day on two consecutive days. A standard dose of 0.1-0.2 mg/kg will be used. All doses used in KIDS-STEP fall into the range of recommended doses according to the Summary of Medical Product Characteristics.
Study: NCT04176016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-111In
Description: single IV injection, 185MBq/body

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTSA101-DTPA-90Y
Description: IV injection (max. 3 injections per patient), 1110MBq/body
Study: NCT01482338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE 20 microgram with desogestrel 150 mg
Description: Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE 20 microgram with drospirenone 3 mg
Description: Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
Study: NCT02036008

Intervention type: OTHER
Group type: OTHER
Intervention: Liver MRI with EcGd
Description: Participants will receive a liver MRI with EcGd as per clinical institutional protocol.~Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.~Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging.
Study: NCT03391414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypertonic bicarbonate
Description: 8.4% sodium bicarbonate inhaled
Study: NCT03861832

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KB220Z
Description: Acts to enhance dopamine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo that looks the same, but does not contain amino acid precursors or any active ingredients in the nutraceutical
Study: NCT03397095

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CSWT+BMMSCs
Description: All participants will screened by D-SPECT to assess the myocardium viability. If the viable myocardium is detected, Patients will be randomized to receive cardiac shock wave therapy with an equipment (Modulith SLC; Storz Medical, Switzerland) followed the recommended protocol developed by Tohoku University of Japan and the protocol developed by the University of Essen, Germany. An over-the-wire catheter will be positioned in the target coronary artery and the cells resuspended in saline will be injected intracoronary.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CSWT+Sham operation
Description: Patients randomized to this group will receive a routine cardiac shock wave therapy and coronary angiography. No cells will be administered via the coronary artery.
Study: NCT01521494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA21

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03434860

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic
Description: The multiprobiotic Symbiter which contains of 14 alive probiotic strains of Lactobacillus + Lactococcus (6×1010 CFU/g), Bifidobacterium (1×1010/g), Propionibacterium (3×1010/g), Acetobacter (1×106/g) genera. Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of probiotic per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Over 8 weeks of interventional period, the patient received 1 sachet (10 grams) of gel per day